<DOC>
	<DOC>NCT00645229</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description>The study was prematurely discontinued due to the difficulty of subject recruitment on March 24, 2005. There were no safety concerns that led to the decision to terminate.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Patients not currently being treated with antipsychotic medication and neuroleptic naive patients Diagnosis of schizophrenia or schizoaffective disorder Antipsychotic treatment prior to screening was to be for a cumulative period of less than 5 years Patients at immediate risk of committing harm to self or others Treatment with clozapine within 3 months prior to baseline History of neuroleptic treatment Current antipsychotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>